Certain disease-modifying therapies (DMTs) for multiple sclerosis (MS) may impair immune responses to vaccines.

We evaluated responder rates, anti-SARS-CoV-2 RBD IgG titers, antigen-specific T cells, and adverse events following SARS-CoV-2 vaccination in people with MS (PwMS) on various DMTs.

Humoral response to mRNA-1273 COVID-19 vaccine was similar in PwMS treated with natalizumab, fumarate, and interferon beta, but muted with ocrelizumab.

T cell response to mRNA-1273 was similar with all DMTs evaluated, including ocrelizumab.

A trend toward greater risk of vaccine-related side effects was observed in the ocrelizumab cohort.